The Polish-Japanese Nomi Biotech Corporation specializes in the design and production of innovative nutraceuticals combining nutritional values and characteristics of pharmaceuticals. Startup has already introduced to the market its first product – the alcorythm® and recently raised EUR 240k investment from the Black Pearls VC fund. The company aims at the USD 100 bn market of functional beverages and develops preparations which support the human body in the fight against the negative effects of alcohol consumption, or the excess of sugars in common food products.
Researchers from Japan and Poland join forces
Industrial scale food manufacturing has radically changed the consumer landscape of developed countries. Paradoxically, an average European consumes 3,200 calories per day, approximately the same amount of calories as 50 years ago. On the other hand, however, the modern food industry creates problems with an excess of some substances in the diet, with sugar and alcohol being the case in point.
Marcin Jaskuła, Nomi Biotech Corporation CEO
Biotechnology vs. modern nutritional habits
Japan is the market leader in nutraceuticals preventing from negative effects of processed food consumption. Due to increased demographic issues as well as high health awareness of the Japanese society, consumers frequently use preventive nutraceuticals. It is the Japanese experience and know-how powered by our local discoveries in increasing bioavailability of natural compounds that we want to implement on the European market.
Kohei Yagi PhD, CTO at Nomi Biotech Corporation
Biotechnology vs “the day after” syndrome
The consumption of alcohol in Poland is systematically growing, but the awareness of the dangers posed by this substance, not. When you add coping with the "day after" ailments with non-steroidal anti-inflammatory drugs, eg. aspirin or ibuprofen into the mix, serious health risks arise. We intend to develop a technology based on a traditional Japanese recipes improved with modern technologies of micronization of molecules and increased bioavailability of active substances. The Black Pearls VC investment is an important step for us in achieving this goal - concludes Nomi Biotech Corporation CEO.
Marcin Jaskuła, Nomi Biotech Corporation CEO
The investment
Nomi Biotech Corporation enters the market with a team of accomplished and renowned scientists and real solutions to real problems deriving from current challenges of civilization and lifestyle.
Maciej Skórkiewicz, Partner at Black Pearls VC
First year of operations - first achievements
The team
Dr Kohei Yagi (PhD), head of the technology and engineering department of the company, is a graduate of the Kyushu Tokai University Faculty of Natural Sciences and doctoral studies at the Warsaw School of Life Sciences in the field of cytogenetics. He is also a renowned Warsaw restaurateur and consultant in the HoReCa industry.
Dr Jakub Urbański (PhD) is in charge of research programs and contacts with academia and research centers at Nomi Biotech Corporation. He is a graduate of the Faculty of Biological Sciences at the University of Warsaw and doctoral studies at the University of Ultrech in the field of molecular biology. Dr Urbański is also a co-founder of HiProMine - the first Polish company dealing in the industrial breeding of insects, in biomass processing.
Michał Żukowski is a graduate of the Faculty of Law and Administration and the Faculty of Journalism and Political Sciences of the University of Warsaw. A solicitor by training, he is the founder of INNTEO - a legal and advisory firm specializing in servicing R&D projects and venture capital funds. He served in several government positions and worked with Poland’s top law firms.
